查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016279

RNA療法市場：依治療領域、遞送系統和最終用戶分類－2026年至2032年全球市場預測

RNA Therapy Market by Therapeutic Area, Delivery System, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年RNA療法市值為187.7億美元，預計到2026年將成長至197億美元，複合年成長率為6.40%，到2032年將達到289.9億美元。

主要市場統計數據
基準年 2025 187.7億美元
預計年份：2026年 197億美元
預測年份 2032 289.9億美元
複合年成長率 (%) 6.40%

這本全面的入門書籍說明了RNA 模式的進步、遞送技術的創新以及法規環境的變化如何匯聚在一起，重新定義治療方法開發途徑。

RNA療法領域已從單純的科學探索轉變為現代生物醫學的核心要素，重塑了研究人員、臨床醫生和產業領袖參與治療方法發現和開發的方式。傳訊RNA、小干擾RNA、反義寡核苷酸及相關技術的進步，在多種適應症中展現出治療潛力，推動了對平台技術、遞送系統和專業生產能力的全新投資。這種轉變體現在轉化醫學研發管線的加速發展、學術機構與產業界策略合作的加強，以及對可擴展和可重複生產流程日益成長的重視。

詳細分析遞送平台、臨床優先排序和經營模式的突破如何共同重塑 RNA 治療生態系統和商業化策略。

RNA療法領域正經歷一系列變革性轉變，這些轉變正在改變研發者和投資者的策略重點。首先，遞送技術正成為關鍵的差異化因素。基於脂質奈米顆粒和新型外泌體平台的製劑能夠實現以往難以實現的全身遞送和組織靶向，而聚合物載體和病毒載體雜交體則提供了互補的方法，可實現持續表達和局部效應。這些遞送技術的進步正在擴大可治療的適應症範圍，影響給藥模式，並對生產要求產生重大影響。

對關稅趨勢將如何影響整個 RNA 療法計畫的供應鏈、籌資策略、臨床重點和製造投資進行詳細評估。

2025年美國可能對原產於美國的商品加徵累積關稅，這將為RNA療法相關企業帶來複雜的營運和策略挑戰。關稅趨勢可能增加脂質、核苷酸、酵素和一次性耗材等關鍵原料的到貨成本，並可能影響質體生產、微流體封裝、層析法系統以及無菌填充和包裝生產線等昂貴設備的供應和價格。不斷上漲的採購成本將迫使研發企業和契約製造製造商重新評估與供應商的關係、庫存策略和採購區域，以確保按時完成專案並維持品質標準。

透過徹底調查不同治療領域、遞送平台權衡和最終使用者行為之間的差異，我們確定了 RNA 介入治療計畫的路線和發展重點。

細分領域的趨勢揭示了科學機會與商業性可行性的交匯點，凸顯了企業在推進基於RNA的干涉療法時必須面對的戰術性選擇。在考慮治療領域細分時，研發人員需要在廣泛適用性和特定適應症的複雜性之間取得平衡。心血管和代謝性疾病計畫追求全身給藥和持續作用；遺傳疾病療法旨在針對單基因疾病進行精準的基因校正和定序；感染疾病策略區分細菌和病毒感染的應對措施；神經系統疾病計畫由於血腦障壁的限制而面臨給藥限制；腫瘤學療法分為骨髓惡性腫瘤和固態腫瘤，二者在免疫腫瘤學方面存在差異；罕見疾病療法則專注於高雪氏症、神經肌肉疾病和鐮狀貧血等特定疾病，這些疾病的臨床終點和監管路徑需要客製化化的證據包。治療領域的這種異質性導致了研發進度、安全性考量和商業性准入策略的差異。

對美洲、歐洲、中東和非洲以及亞太地區的生態系統如何對創新、製造能力、監管合規性和准入策略產生不同的影響進行全面的區域評估。

區域趨勢正以不同的方式影響RNA療法研發和商業化領域的商業決策。在美洲，強大的創業投資系統、領先的學術醫療中心和先進的製造基礎設施為早期創新和快速臨床應用提供了肥沃的環境。由國家監管機構管理的監管路徑強調嚴格的安全性和有效性證據，而專業契約製造和服務供應商的集中則加快了能夠連接這些網路的專案進入臨床試驗的時間。

本文深入分析了平台領導、策略夥伴關係、製造專業知識和監管合作如何使 RNA 治療領域中最有效的組織脫穎而出。

在RNA療法領域，領先的企業透過平台深度、策略夥伴關係和生產能力三者的組合來脫穎而出。以平台為中心的創新者正投資於基礎技術，以實現跨多個適應症的快速迭代開發，並優先考慮模組化設計、可靠的表徵方法以及用於支援監管諮詢的資料包。合約開發和生產公司認知到，先進的技術能力是應對複雜RNA專案的競爭優勢，因此正在擴展其在脂質體製劑、分析方法開發以及無菌填充和包裝方面的專業服務。

為高階主管提供實務指導，以協調平台選擇、供應鏈韌性、監管參與和商業化準備，從而加速臨床影響。

為了將科學突破轉化為永續的治療效果，產業領導者必須採取務實且協作的行動，在創新與營運嚴謹性之間取得平衡。應優先投資於與目標適應症相符的給藥平台，確保製劑的選擇既有生物證據支持，又具備下游生產的可行性。早期專案應包含分析方法開發和製程表徵，以最大限度地減少後期階段可能出現的意外問題，並縮短從研究到符合GMP規範生產的過渡時間。

對一種跨學科研究途徑的透明說明，該方法結合了技術文獻綜述、監管分析、臨床註冊研究和主要專家訪談，以得出可靠的研究結果。

本研究整合了來自同行評審科學文獻、監管指導文件、臨床試驗註冊庫、專利趨勢、生產技術報告以及對行業高管、科學家和監管專家的訪談證據。透過跨資料來源的三角驗證，本研究檢驗了技術趨勢、給藥平台的可行性以及營運限制，從而保持了分析的嚴謹性。定性訪談提供了有關決策流程、合作理由和生產考慮的背景信息，而二手資料則提供了對過往先例和監管變化的見解。

結論強調，要實現 RNA 技術的治療潛力，需要將科學創新、製造成熟度和相關人員的參與結合起來。

RNA療法正處於一個轉折點，技術成熟、臨床應用目標不斷擴大以及監管預期不斷演變，三者在此交匯，創造了巨大的轉化應用機會。未來的進展將同樣取決於分子設計和遞送技術的創新，以及執行複雜生產專案、應對供應鏈波動和與整個醫療生態系統相關人員合作的組織能力。那些兼具卓越科研實力和前瞻性營運能力的機構，將能夠推動治療方法，滿足未被滿足的醫療需求，同時應對商業化和市場准入方面的實際挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 RNA療法市場：依治療領域分類

  • 心血管疾病
  • 遺傳性疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
  • 罕見疾病
    • 高雪氏症
    • 神經肌肉疾病
    • 鐮狀細胞貧血症

第9章 RNA療法市場按遞送系統分類

  • 外泌體
  • 脂質奈米顆粒
  • 聚合物載體
  • 病毒載體

第10章 RNA療法市場：依最終用戶分類

  • 生技公司
  • 醫院和診所
  • 製藥公司
  • 研究機構

第11章 RNA療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 RNA療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 RNA療法市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 美國RNA療法市場

第15章 中國RNA療法市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech SE
  • CureVac NV
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics plc
  • Stoke Therapeutics
Product Code: MRR-0375F3EAA7E7

The RNA Therapy Market was valued at USD 18.77 billion in 2025 and is projected to grow to USD 19.70 billion in 2026, with a CAGR of 6.40%, reaching USD 28.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.77 billion
Estimated Year [2026] USD 19.70 billion
Forecast Year [2032] USD 28.99 billion
CAGR (%) 6.40%

Comprehensive primer explaining how advancements in RNA modalities, delivery innovations, and regulatory evolution are converging to redefine therapeutic development pathways

The field of RNA therapeutics has moved from scientific curiosity to a central pillar of contemporary biomedicine, reshaping how researchers, clinicians, and industry leaders approach treatment discovery and development. Advances in messenger RNA, small interfering RNA, antisense oligonucleotides, and related modalities have demonstrated therapeutic potential across a wide spectrum of indications, stimulating renewed investment in platform technologies, delivery systems, and specialized manufacturing capabilities. This transition is reflected in accelerated translational pipelines, strategic collaborations between academic institutions and industry, and a growing emphasis on scalable, reproducible production processes.

Technological maturation has been matched by evolving regulatory expectations and clinical evidence requirements, prompting developers to refine trial designs, safety monitoring approaches, and comparator choices. Meanwhile, improvements in delivery vectors, formulation chemistry, and analytical methods have reduced barriers to entry for new developers while raising the bar for differentiation. Consequently, organizations now prioritize platform robustness, cross-indication applicability, and the ability to demonstrate consistent performance across diverse patient populations.

As stakeholders evaluate next steps, the industry must integrate scientific progress with pragmatic operational planning. Manufacturing capacity, supply chain resilience, and regulatory engagement are now as critical as target selection and preclinical efficacy. In short, RNA therapeutics sits at a pivotal juncture where scientific promise must be matched by execution excellence to translate into durable clinical and commercial outcomes.

Detailed analysis of how breakthroughs in delivery platforms, clinical prioritization, and business models are jointly reshaping the RNA therapeutics ecosystem and commercialization strategies

The landscape for RNA therapeutics is undergoing a sequence of transformative shifts that alter strategic priorities for developers and investors alike. First, delivery science has emerged as a primary differentiator: formulations based on lipid nanoparticles and emerging exosome platforms are enabling systemic delivery and tissue targeting that were previously elusive, while polymer carriers and viral vector hybrids offer complementary approaches for sustained expression or localized effect. These delivery advances expand the range of treatable indications, influence dosing paradigms, and materially affect manufacturing requirements.

Second, there is a clear reorientation of clinical focus toward complex and previously intractable indications. Oncology programs increasingly explore RNA-mediated modulation of tumor biology and immune activation for both hematological malignancies and solid tumors, while rare disease efforts harness gene-silencing and replacement strategies to address genetic disorders such as Gaucher disease, neuromuscular disorders, and sickle cell disease. Infectious disease applications, including targeted approaches for viral infections and novel antibacterial RNA strategies, retain strategic importance given global public health priorities and the capability of RNA platforms to accelerate response timelines.

Third, the business model is shifting as platform-centric companies seek to monetize broad technology stacks through licensing, strategic alliances, and vertical integration. Contract development and manufacturing organizations are expanding capabilities to service high-containment production and lipid nanoparticle encapsulation, and hospitals and clinics are beginning to engage with advanced therapies in new ways as clinical delivery paradigms evolve. Research institutes continue to feed innovation, creating a dynamic innovation pipeline that is increasingly interdependent across sectors.

Finally, heightened attention to regulatory and payer evidence is reshaping go-to-market strategies. Developers are investing in real-world evidence generation, longitudinal safety monitoring, and health economics studies that support reimbursement discussions and policy adoption. Taken together, these shifts signal a transition from discrete, proof-of-concept achievements to sustained, system-level integration of RNA therapeutics into clinical practice.

In-depth assessment of how tariff developments can alter supply chains, sourcing strategies, clinical prioritization, and manufacturing investments across RNA therapeutic programs

The potential imposition of cumulative tariffs originating from the United States in 2025 presents a complex set of operational and strategic challenges for organizations involved in RNA therapeutics. Tariff dynamics can increase landed costs for critical raw materials such as lipids, nucleotides, enzymes, and single-use consumables, and they can also affect the availability and pricing of high-value capital equipment used for plasmid production, microfluidic encapsulation, chromatography systems, and sterile fill-finish lines. When procurement costs rise, developers and contract manufacturers are pressured to reassess supplier relationships, inventory strategies, and sourcing geographies to preserve program timelines and maintain quality standards.

In response to tariff-driven cost pressures, companies may accelerate efforts to localize supply chains, expanding domestic production of key inputs or negotiating longer-term procurement agreements to stabilize pricing. While localization can reduce exposure to cross-border tariffs, it often requires significant capital investment and operational lead time, particularly when specialized manufacturing attributes or regulatory approvals are necessary. As a result, smaller developers and research institutes that lack in-house production capabilities may be disproportionately affected, compelling greater reliance on regional contract manufacturers and strategic partners.

Tariffs can also influence clinical development decisions. Increased input costs may cause sponsors to optimize trial designs to reduce material usage per patient, to prioritize indications with clearer pathways to reimbursement, or to sequence programs based on resource intensity. For hospitals and clinics, procurement budgets could be squeezed, potentially affecting adoption cycles for advanced therapies that require complex delivery or supportive infrastructure. Investors and strategic partners will therefore scrutinize the resilience of supply chain plans and the feasibility of production scale-up under altered cost structures.

Finally, the political and regulatory signaling associated with tariff policy can have reputational and strategic implications. Heightened trade tensions may encourage multinational firms to diversify manufacturing footprints across multiple regions to avoid exposure to single-jurisdiction policy shifts. At the same time, bilateral and multilateral dialogues can create pathways for exemptions or tariff mitigation mechanisms for critical healthcare supplies, underscoring the importance of active engagement with policymakers and industry associations. In short, tariff developments in 2025 could catalyze structural adjustments across procurement, manufacturing strategy, and clinical program prioritization, with tangible implications for timelines and partnership models.

Rigorous exploration of therapeutic area distinctions, delivery platform trade-offs, and end-user behaviors that together define program pathways and development priorities for RNA interventions

Segment-level dynamics reveal where scientific opportunity and commercial viability intersect, and they illuminate the tactical choices organizations must confront when advancing RNA-based interventions. Examining therapeutic area segmentation, developers are balancing broad applicability against indication-specific complexity: cardiovascular and metabolic disorder programs pursue systemic delivery and sustained activity, genetic disorder initiatives target precise gene correction or silencing for monogenic conditions, infectious disease strategies differentiate between bacterial approaches and viral infection countermeasures, neurological programs grapple with blood-brain barrier delivery constraints, oncology efforts split between hematological malignancies and solid tumors with differing immuno-oncology considerations, and rare disease pursuits concentrate on specific conditions such as Gaucher disease, neuromuscular disorders, and sickle cell disease where clinical endpoints and regulatory pathways demand bespoke evidence packages. This therapeutic heterogeneity drives divergent development timelines, safety considerations, and commercial access strategies.

When viewed through the lens of delivery system segmentation, contrasts become even more pronounced. Exosome-based strategies promise biologically native delivery and potential immune stealth but face manufacturing and characterization challenges that require advanced analytical capacity. Lipid nanoparticle technologies have become the de facto solution for many systemic applications due to demonstrated scalability and established regulatory precedents, yet they demand rigorous control of excipients and process parameters. Polymer carriers offer tunable release profiles and modular design but frequently require extensive biocompatibility validation, while viral vectors deliver robust transgene expression for certain applications at the cost of immunogenicity and complex regulatory scrutiny. The choice of delivery platform not only affects clinical performance but also determines upstream supplier needs, facility design, and the depth of analytical development required for regulatory submissions.

End-user segmentation shapes commercialization and adoption strategies in practical ways. Biotechnology companies often lead innovation and platform development, focusing on intellectual property creation and clinical proof of concept. Pharmaceutical companies bring late-stage development, regulatory experience, and global commercialization infrastructure, enabling broader market access when clinical and payer evidence align. Hospitals and clinics play a critical role in adoption for therapies that require specialized administration, long-term monitoring, or integration into existing care pathways, and their procurement criteria increasingly emphasize demonstrable clinical benefit and operational feasibility. Research institutes remain essential sources of discovery and translational expertise, frequently partnering with industry to de-risk early science and catalyze new platform iterations.

Taken together, these segmentation insights underscore the necessity of aligning therapeutic targets, delivery choices, and end-user engagement strategies early in program planning. Developers that explicitly account for the interplay among indication characteristics, platform constraints, and end-user requirements are better positioned to design clinical programs that meet regulatory expectations and accelerate acceptance in clinical practice.

Comprehensive regional appraisal of how Americas, EMEA, and Asia-Pacific ecosystems differentially influence innovation, manufacturing capacity, regulatory navigation, and access strategies

Regional dynamics shape the operational calculus for research, development, and commercialization of RNA therapies in distinct ways. In the Americas, robust venture capital ecosystems, leading academic medical centers, and advanced manufacturing infrastructure provide a fertile environment for early-stage innovation and rapid clinical translation. Regulatory pathways administered by national authorities emphasize rigorous safety and efficacy evidence, and the concentration of specialized contract manufacturers and service providers reduces time-to-clinic for programs that can access these networks.

Europe, the Middle East, and Africa present a mosaic of regulatory regimes and payer structures that require nuanced market access planning. The European regulatory framework promotes centralized review pathways that can support cross-border approvals, while health systems across the region emphasize cost-effectiveness and real-world therapeutic value. Emerging markets within the region are experiencing growing biotech activity and clinical trial participation, offering opportunities for enrollment and partnership but necessitating tailored regulatory and reimbursement strategies.

Asia-Pacific is characterized by rapid capacity expansion, substantial public and private investment in biopharmaceutical manufacturing, and an increasing number of skilled scientific and technical personnel. Several jurisdictions are actively streamlining regulatory processes for advanced therapies and incentivizing domestic production, which can accelerate timelines for locally developed programs. Nevertheless, regional supply chain dependencies and variable regulatory harmonization require companies to adopt diversified sourcing approaches and proactive regulatory engagement to ensure smooth program progression across multiple jurisdictions.

Insightful summary of how platform leadership, strategic alliances, manufacturing specialization, and regulatory engagement distinguish the most effective organizations in RNA therapeutics

Leading organizations operating in the RNA therapeutics domain differentiate themselves through a combination of platform depth, strategic partnerships, and manufacturing capabilities. Platform-centric innovators invest in foundational technologies that enable rapid iteration across multiple indications, prioritizing modular design, robust characterization methods, and data packages that support regulatory discussions. Contract developers and manufacturers are expanding specialized services for lipid nanoparticle formulation, analytical method development, and aseptic fill-finish, recognizing that deep technical capability is a competitive advantage when serving complex RNA programs.

Collaborative models have become central to business strategies. Strategic alliances between technology developers and larger pharmaceutical organizations enable resource pooling for late-stage development and global commercialization, while academic and clinical partnerships accelerate translational research and facilitate patient access for early trials. Some organizations pursue vertical integration to secure critical inputs and reduce exposure to external supply volatility, whereas others focus on niche specialization-such as exosome isolation or polymer carrier chemistry-to command unique value propositions.

Operational excellence is increasingly visible in the firms that succeed in this space. Companies that have invested early in scalable analytics, robust process controls, and regulatory science expertise move more efficiently through clinical development and engage payers more credibly. Additionally, those that cultivate open channels with regulators and health technology assessment bodies tend to reduce approval friction and achieve smoother reimbursement discussions. In aggregate, the industry favors entities that combine scientific leadership with pragmatic execution capabilities across manufacturing, regulatory, and commercial functions.

Action-oriented guidance for executives to align platform selection, supply chain resilience, regulatory engagement, and commercialization readiness to accelerate clinical impact

To convert scientific breakthroughs into sustainable therapeutic impact, industry leaders must adopt pragmatic, coordinated actions that balance innovation with operational rigor. Prioritize investment in delivery platforms that align with targeted indications, ensuring that formulation choices are justified by both biological rationale and downstream manufacturing feasibility. Early-stage programs should incorporate analytical development and process characterization to minimize late-stage surprises and to shorten timelines when transitioning from research to GMP production.

Strengthening supply chain resilience is essential. Companies should evaluate dual-sourcing strategies for critical raw materials, consider regional manufacturing options to mitigate cross-border policy exposure, and negotiate long-term agreements that secure access to specialized consumables. Simultaneously, organizations should pursue strategic collaborations with contract developers and academic centers to de-risk technical hurdles while maintaining flexibility in portfolio decision-making.

Engagement with regulators, payers, and clinical stakeholders must begin early and continue iteratively. Developers should design clinical programs that capture endpoints meaningful to both regulators and reimbursement authorities, and they should invest in real-world evidence infrastructures that demonstrate long-term value. Finally, cultivate a disciplined approach to commercialization by aligning clinical development pathways with realistic operational capabilities, thereby ensuring that scientific advances can be delivered reliably to patients at scale.

Transparent description of the multidisciplinary research approach combining technical literature review, regulatory analysis, clinical registry inspection, and primary expert interviews for robust insight generation

This research synthesizes evidence from peer-reviewed scientific literature, regulatory guidance documents, clinical trial registries, patent landscapes, manufacturing technology reports, and primary interviews with industry executives, scientists, and regulatory experts. Analytical rigor was maintained through triangulation across data sources to validate technology trends, delivery platform feasibility, and operational constraints. Qualitative interviews provided context on decision-making processes, partnership rationales, and manufacturing considerations, while secondary sources informed historical precedent and regulatory evolution.

Methodological safeguards included cross-validation of technical claims with multiple domain experts, verification of manufacturing and formulation challenges against facility design documentation, and careful attention to regulatory language to ensure accurate interpretation of approval pathways. The approach prioritized disclosure of assumptions and sought to isolate practice patterns from transient events, thereby focusing on durable trends with operational relevance. Throughout the study, emphasis was placed on actionable insight rather than speculative projection, enabling practitioners to apply findings directly to program planning and strategic decision-making.

Concluding synthesis emphasizing the necessity of combining scientific innovation, manufacturing maturity, and stakeholder engagement to realize the therapeutic potential of RNA technologies

RNA therapeutics stand at an inflection point where technological maturity, expanding clinical ambition, and evolving regulatory expectations converge to create substantial translational opportunity. Continued progress will depend not only on innovations in molecular design and delivery but equally on the ability of organizations to execute complex manufacturing campaigns, manage supply chain dynamics, and engage stakeholders across the healthcare ecosystem. Those that integrate scientific excellence with operational foresight will be positioned to advance therapies that address unmet medical needs while navigating the practical realities of commercialization and access.

As the field progresses, attention to platform reproducibility, end-user integration, and evidence generation will determine which programs achieve clinical adoption and sustained impact. The coming years will likely favor multidisciplinary teams that combine molecular biology, formulation chemistry, process engineering, and regulatory science to convert laboratory breakthroughs into reliable, scalable treatments for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Therapy Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
    • 8.3.1. Bacterial Infections
    • 8.3.2. Viral Infections
  • 8.4. Metabolic Disorders
  • 8.5. Neurological Disorders
  • 8.6. Oncology
    • 8.6.1. Hematological Malignancies
    • 8.6.2. Solid Tumors
  • 8.7. Rare Diseases
    • 8.7.1. Gaucher Disease
    • 8.7.2. Neuromuscular Disorders
    • 8.7.3. Sickle Cell Disease

9. RNA Therapy Market, by Delivery System

  • 9.1. Exosomes
  • 9.2. Lipid Nanoparticles
  • 9.3. Polymer Carriers
  • 9.4. Viral Vectors

10. RNA Therapy Market, by End User

  • 10.1. Biotechnology Companies
  • 10.2. Hospitals & Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutes

11. RNA Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States RNA Therapy Market

15. China RNA Therapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Alnylam Pharmaceuticals, Inc.
  • 16.6. Arcturus Therapeutics Holdings, Inc.
  • 16.7. Arrowhead Pharmaceuticals, Inc.
  • 16.8. BioNTech SE
  • 16.9. CureVac N.V.
  • 16.10. Eli Lilly and Company
  • 16.11. Ionis Pharmaceuticals, Inc.
  • 16.12. Moderna, Inc.
  • 16.13. Sarepta Therapeutics, Inc.
  • 16.14. Silence Therapeutics plc
  • 16.15. Stoke Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 142. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 145. GCC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 166. G7 RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 172. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 173. NATO RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)